OncClubAll Oncology NewsPipeline Report
InsightsMedical World NewsOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsThe Talk
Conference CoverageConference Listing
Giants of Cancer CarePER EventsScientific InterchangesState of the Science Summit / IPCWebinars
Partners
Oncology Live®Oncology FellowsSupplements And Featured PublicationsAll Publications
CME/CE
Biomarker ConsortiumInteractive ToolsLearning ModulesPresentationsSponsored
Print SubscriptioneNewsletter
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
Spotlight -
  • REGISTER TODAY to explore data on a novel second-generation BTK inhibitor for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
  • Share your views with OncChats
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
Business Management
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-OncologyImmuno-OncologyImmuno-OncologyImmuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Nursing News
Pediatric Oncology
Precision Medicine in Oncology®Precision Medicine in Oncology®
Sarcomas/TGCT
Supportive Care
    • Partners
    • CME/CE
Advertisement

Treatment of Advanced Head & Neck Squamous Cell Carcinoma

home / insights / hnscc-treatment
Advertisement
Biology of Head and Neck Squamous Cell Carcinoma

EP. 1: Biology of Head and Neck Squamous Cell Carcinoma

March 21st 2016
HPV Infection in Pathogenesis of Head and Neck Cancers

EP. 2: HPV Infection in Pathogenesis of Head and Neck Cancers

March 21st 2016
Challenges in Implementing Widespread HPV Vaccination

EP. 3: Challenges in Implementing Widespread HPV Vaccination

March 21st 2016
Diagnosis, Staging, and Prognosis of Head and Neck Cancer

EP. 4: Diagnosis, Staging, and Prognosis of Head and Neck Cancer

March 21st 2016
Multidisciplinary Care in Head and Neck Cancer

EP. 5: Multidisciplinary Care in Head and Neck Cancer

March 21st 2016
Treatment Approaches in Head and Neck Cancer

EP. 6: Treatment Approaches in Head and Neck Cancer

March 21st 2016
Advertisement
Head and Neck Cancer: Treatment of Advanced Disease

EP. 7: Head and Neck Cancer: Treatment of Advanced Disease

March 21st 2016
Surgical Management of HNSCC

EP. 8: Surgical Management of HNSCC

March 21st 2016
Radiation Therapy Approaches to Head and Neck Cancer

EP. 9: Radiation Therapy Approaches to Head and Neck Cancer

March 21st 2016
Roles for Radiotherapy in Head and Neck Cancer

EP. 10: Roles for Radiotherapy in Head and Neck Cancer

March 21st 2016
Chemotherapy Procedures for Advanced HNSCC

EP. 11: Chemotherapy Procedures for Advanced HNSCC

March 21st 2016
Examining the Use of Cetuximab for HNSCC

EP. 12: Examining the Use of Cetuximab for HNSCC

March 21st 2016
Advertisement
When to Use Cetuximab or Chemotherapy in HNSCC

EP. 13: When to Use Cetuximab or Chemotherapy in HNSCC

March 21st 2016
Supportive Care and Long-Term Quality of Life in HNSCC

EP. 14: Supportive Care and Long-Term Quality of Life in HNSCC

March 21st 2016
The Use of Immunotherapy in HNSCC

EP. 15: The Use of Immunotherapy in HNSCC

March 21st 2016
Emerging Therapies in HNSCC

EP. 16: Emerging Therapies in HNSCC

March 21st 2016

Latest Conference Coverage

Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis

Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment

First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma

Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
CancerNetwork.com
CGTlive.com
CureToday.com
OncNursingNews.com
TargetedOnc.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact